CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 48 enrolled
Drug / intervention
Suvorexant +1 moredrug
Likely dose
Suvorexant 10mg or 20mg orally at bedtime for two consecutive nightsAI-extracted
Key inclusion· 3
  • ✓Age 45-65 years
  • ✓Mini-Mental Status Examination score ≥27 (cognitively normal)
  • ✓Sleep efficiency measured by actigraphy to stratify good or poor sleepers
Key exclusion· 18
  • ✕Cognitive impairment (MMSE <27)
  • ✕Sleep disorders other than insomnia
  • ✕History of sleep-disordered breathing or STOP-Bang score >3
  • ✕Restless legs syndrome, narcolepsy, or other sleep disorders

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03077620
NCT03077620N/ACompleted
CompareCT.gov

Sleep Quality and Amyloid-Beta Kinetics

Washington University School of Medicine·interventional·Posted Mar 13, 2017·Updated May 17, 2022

In Brief

A clinical study evaluating Suvorexant and Placebo for Amyloid-beta. Completed, enrolled 48 participants across 1 site.

Detailed Summary

The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) by modification of sleep efficiency.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyloid-beta
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 13, 2017
Enrollment StartNov 1, 2016
Primary CompletionMar 28, 2021
Study CompletionMar 30, 2021
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 9.3 years ago

Interventions

Suvorexantdrug

Participants will be given a sleep aid (10mg or 20mg suvorexant) at bedtime for two consecutive nights that they are spending in a research unit.

Placebodrug

Participants will be given a placebo at bedtime for two consecutive nights that they are spending in a research unit.